Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Long Term US Stocks to Buy Now. On December 16, Daiwa analyst ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Ash will provide at-home biomarker testing to Noom users to provide insights into key health markers linked to chronic ...

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

Novo Nordisk (whose injectable weight-loss medication Wegovy is shown here) and rival Eli Lilly are both developing a new generation of obesity drugs. Eli Lilly and Novo Nordisk - the dominant players ...

Pfizer ( PFE +0.26%) and Eli Lilly ( LLY +1.80%) are two prominent names in healthcare that have focused on innovation and ...

Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...